You are here:  Home  >  Israel  >  Current Article

Israeli Entrepreneur Sets to Take Stem Cell Research to the NASDAQ Trading Floor

By   /   February 16, 2016  /   No Comments

    Print       Email

Kfar Saba (TPS) – Cellect Biotechnology Ltd., an Israeli developer of a technological platform which enables the functional selection of stem cells, has successfully raised over $2 million and has brought itself closer to being traded internationally on the NASDAQ in New York.

The initial sum was raised through a non-public offering of Cellect shares and securities to a small number of selected investors from Israel and abroad.

Nuriel Chirich Kasbian is the primary investor with a 21% share of the company and the chairman of the board of directors. He is a former executive media producer and has worked at the Golan-Globus studios and at the national Israel Broadcasting Authority.

    Print       Email
  • Published: 5 years ago on February 16, 2016
  • By:
  • Last Modified: February 16, 2016 @ 3:19 pm
  • Filed Under: Israel

Leave a Reply

You might also like...

Donald Trump and the mythmakers, by Caroline B. Glick (Israel Hayom)

Read More →